37 results
PRE 14A
SYRS
Syros Pharmaceuticals Inc.
12 Apr 24
Preliminary proxy
4:30pm
oncology lung franchise from 2015 to 2018, as well as in multiple U.S. sales and marketing leadership roles. Prior to joining Novartis, Mr. Chee spent five … Steering Committee and serves on several external advisory boards of NCI-designated cancer centers, was a lead mentor in ASCO’s Leadership Development
8-K
EX-99.1
SYRS
Syros Pharmaceuticals Inc.
8 Jan 24
Regulation FD Disclosure
7:06am
-4Q 24
Experienced leadership team with proven capabilities and expertise in launching targeted oncology medicines Planning our distribution and sales
8-K
EX-99.1
f9r 2qmze
16 Sep 22
Syros Announces Closing of Merger with Tyme Technologies and Concurrent Private Placement
4:15pm
424B3
mdxkspkn8
8 Aug 22
Prospectus supplement
5:47pm
S-4
422oy
18 Jul 22
Registration of securities issued in business combination transactions
7:58am
425
v1uap2p3c 26mw
6 Jul 22
Business combination disclosure
4:30pm
8-K
EX-99.1
m21uwmi kfmdmgwevx
6 Jul 22
Other Events
4:27pm
8-K
EX-99.1
5wzb9wbxklbwioed
5 Jul 22
Syros to Raise Approximately $190 Million Through Merger with TYME Technologies and Concurrent Private Placement
7:07am
8-K
EX-99.1
ra3vh0vwjs6pygzj
20 Sep 21
Regulation FD Disclosure
4:02pm
8-K
EX-99.1
yzkx6t2g7
26 May 21
Regulation FD Disclosure
8:30am
8-K
EX-99.1
kl316 5xnbtg
25 Feb 21
Regulation FD Disclosure
7:01am
8-K
EX-99.1
52ql1a4xvl7
11 Jan 21
Syros Announces Strategic Priorities and Expected Milestones
7:53am
8-K
EX-99.1
vi62nrdpyi
7 Dec 20
Entry into a Material Definitive Agreement
6:05am